Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 15/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.62 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515340 | 0.91 | FYN (0.55) | FYNDYRK1ADYRK3CCNT1CDK9 | |
| SCHEMBL3515931 | 0.84 | FYN (0.71) | FYN | |
| SCHEMBL3516230 | 0.82 | FYN (0.58) | FYNDYRK1ADYRK3CCNT1CDK9 | |
| SCHEMBL3516147 | 0.82 | FYN (0.73) | FYN | |
| SCHEMBL857188 | 0.80 | CDK8 (0.66) | CCNT1CDK9CDK5DYRK1B | |
| SCHEMBL18613455 | 0.79 | FYN (1.00) | FYNDYRK1A | |
| SCHEMBL30521791 | 0.79 | FYN (1.00) | FYNDYRK1A | |
| SCHEMBL16331517 | 0.78 | FYN (0.77) | FYNDYRK1ADYRK3CCNT1CDK9 | |
| SCHEMBL18613710 | 0.78 | FYN (1.00) | FYNDYRK1A | |
| SCHEMBL20485689 | 0.78 | FYN (0.72) | FYNDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | claimed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | FYN 425/4885DYRK1A 2632/4885DYRK3 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.